NYSE$IBIO
iBio Inc · Q4 2024 earnings
Q4 2024 earnings · · Investor relations
Briefing
iBio's fiscal year 2024 financial results were announced, and a corporate update was provided.
iBio reported a transformational fiscal year 2024, marked by strategic business developments including expanding the AI-powered technology stack, the sale of the PD-1 asset to Otsuka Pharmaceutical, and entering into a collaboration with AstralBio. The company strengthened its financial position through capital raises and debt extinguishment. However, the audit report contained an explanatory paragraph related to the company's ability to continue as a going concern.
- iBio launched ShieldTx™, a patent-pending antibody masking technology.
- iBio sold its early-stage PD-1 asset to Otsuka Pharmaceutical Co., Ltd. for $1MM upfront with potential downstream payments.
- iBio entered into a collaboration with AstralBio, Inc. for an exclusive license in the cardiometabolic and obesity space.
- iBio closed a private placement for gross proceeds of approximately $15.0MM in the fiscal fourth quarter.
Headline financials
Revenue & EPS history
iBio · Revenue · Quarterly
$175K
Forward guidance
iBio expects to advance its technology to drive value for patients and shareholders and to strengthen its financial position.
Tailwinds
- Advance technology to drive value for patients
- Advance technology to drive value for shareholders
- Continue to pursue business development projects
- Strengthen the Company’s financial position
- Decrease drug failures
Headwinds
- Ability to successfully advance its technology
- Ability to successfully continue to pursue business development projects
- Ability to obtain regulatory approvals for commercialization of its product candidates
- Ability to comply with ongoing regulatory requirements
- Substantial doubt exists related to the Company’s ability to operate as a going concern
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-1.4%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+14.3%
Avg return
30 days after
43%
17 / 40 earnings
Positive
+24.4%
Q3 2020
Best reaction
-34.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +12.9% | +9.9% | +22.8% | |
| Q1 2026 | -8.0% | -3.2% | +55.2% | |
| Q4 2025 | +3.7% | +8.6% | +6.2% | |
| Q3 2025 | +1.3% | +1.3% | +30.4% | |
| Q2 2025 | -14.8% | -7.8% | +49.2% | |
| Q1 2025 | -9.4% | -10.9% | -2.0% | |
| Q4 2024 | -2.6% | -4.2% | +51.1% | |
| Q3 2026 | -3.7% | +23.9% | +36.2% | |
| Q3 2024 | +1.6% | +7.0% | +37.8% | |
| Q2 2024 | +5.2% | +5.2% | +2.6% | |
| Q1 2024 | -3.4% | -10.3% | -78.1% | |
| Q4 2023 | -3.3% | -9.1% | -6.1% | |
| Q3 2023 | -7.9% | -5.9% | -31.7% | |
| Q2 2023 | -10.5% | +55.8% | +113.7% | |
| Q1 2023 | +0.0% | -8.6% | -68.6% | |
| Q4 2022 | -34.4% | -46.9% | -74.6% | |
| Q3 2022 | +0.0% | +0.0% | +12.0% | |
| Q2 2022 | +2.7% | -8.1% | -5.4% | |
| Q1 2022 | -9.2% | -11.8% | -17.1% | |
| Q4 2021 | -4.3% | -11.1% | -35.0% | |
| Q3 2021 | -6.8% | -0.7% | +5.4% | |
| Q2 2021 | -15.3% | -17.8% | -29.8% | |
| Q1 2021 | +15.2% | -9.6% | -38.2% | |
| Q3 2020 | +24.4% | +16.0% | +31.9% | |
| Q2 2020 | -10.5% | -21.1% | +321.1% | |
| Q1 2020 | +13.3% | -26.7% | +46.7% | |
| Q3 2019 | +7.3% | -2.4% | -4.9% | |
| Q2 2019 | -2.2% | -4.4% | -6.7% | |
| Q1 2019 | +4.0% | +9.3% | -10.7% | |
| Q1 2015 | +3.4% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q1 2013 | -1.9% | — | — | |
| Q3 2012 | -9.8% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q4 2011 | -3.0% | — | — | |
| Q3 2011 | +4.8% | — | — | |
| Q2 2010 | +3.4% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q3 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro